Abstracts

Citation

Edmund Capparelli, Pharm.D., Suzette Blanchard, M.S., Ph.D., Francesca Aweeka, Pharm.D., Edward P. Acosta, Pharm.D. Population pharmacokinetics of nevirapine in infants and children - the impact of body size, age, and concomitant therapies. Presented at: 6th Int'l Workshop on Clinical Pharmacology of HIV Therapy.

Citation

Ellen Gould Chadwick, M.D., John H. Rodman, Pharm.D., Paul Palumbo, M.D., Deborah Persaud, M.D., Jie (Ellen) Chen, M.S., Jennifer L. Gardella, M.P.H., Katherine Luzuriaga, M.D., Patricia J. Emmanuel, M.D., Mobeen H. Rathore, M.D., Ram Yogev, M.D. A prospective evaluation of pharmacologic, virologic, and immunologic parameters of lopinavir/ritonavir for HIV-1 infected infants 6 months of age. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Akihiko Saitoh, M.D., Christine Powell, M.A., Terence Fenton, Ed.D., Courtney V. Fletcher, Pharm.D., Stephen A. Spector, M.D. HLA B44 allele and B44 supertype effect on the response to HAART in HIV-1-infected children. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Georgia D. Tomaras, Ph.D., Elizabeth (Betsy) J. McFarland, M.D., Daniel Johnson, M.D., Petronella Muresan, M.S., Terence Fenton, Ed.D., Vicki C. Ashley, David C. Montefiori, Ph.D., John S. Lambert, M.D., James McNamara, M.D., Elizabeth Hawkins, Barbara E. Heckman, B.S., Jennifer S. Read, M.D., M.P.H., M.S., DTM&H, Scharla Estep, M.S., R.Ph., Sanjay Gurunathan, M.D., Marc Gurwith, M.D. Anti-HIV antibodies elicited by prime boost vaccination, vCP1452 + AIDSVAX B/B, in newborns of HIV-infected mothers. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Kumud K. Singh, Michael Hughes, Ph.D., Jie (Ellen) Chen, M.S., Kelesitse Phiri, C. Rousseau, Louise Kuhn, Beverly A. Jackson, R.N., R. Semba, Stephen A. Spector, M.D. CX3CR1-249 polymorphism is important determinant of risk of perinatal transmission of HIV-1 in African children. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Jennifer J. Kiser, Pharm.D., Richard M. Rutstein, M.D., Grace M. Aldrovandi, MD, Pearl Samson, M.S., Bobbie L. Graham, B.S., Steven M. Schnittman, M.D., Elizabeth (Betsy) Smith, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Courtney V. Fletcher, Pharm.D. Pharmacokinetics (PK) of atazanivir/ritonavir (ATV/RTV) in HIV-infected infants, children, and adolescents: Pediatric AIDS Clinical Trials Group (PACTG) 1020A. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Elizabeth (Betsy) J. McFarland, M.D., Daniel Johnson, M.D., Petronella Muresan, M.S., Terence Fenton, Ed.D., James McNamara, M.D., Elizabeth Hawkins, Barbara E. Heckman, B.S., Jennifer S. Read, M.D., M.P.H., M.S., DTM&H, Scharla Estep, M.S., R.Ph., Sanjay Gurunathan, M.D., Marc Gurwith, M.D., John S. Lambert, M.D. Safety and cell-mediated immune responses to a prime-boost immunization with ALVAC HIV vaccine and AIDSVAX B/B in newborns of HIV-infected mothers (PACTG 326). Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Paige L. Williams, Ph.D., Betsy Kammerer, Ph.D., Grace Montepiedra, Ph.D., Sharon L. Nichols, Ph.D., Patricia Sirois, Ph.D., Deborah S. Storm, R.N.,Ph.D, John J. Farley, M.D., M.P.H., Kathleen Malee, Ph.D. Characterization of medication adherence in children and adolescents with HIV infection. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Bret J. Rudy, M.D., Jane C. Lindsey, Sc.D., Michael Hughes, Ph.D., Patricia M. Flynn, M.D., M.S. The impact of adherence in adolescents initiating HAART: data from the PACTG 381 cohort. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Bret J. Rudy, M.D., Jane C. Lindsey, Sc.D., Patricia M. Flynn, M.D., M.S., Ronald J. Bosch, Ph.D., Craig M. Wilson, M.D., Janice Hodge, R.N., B.S., Michael Hughes, Ph.D., Steven D. Douglas, M.D. Immune reconstitution and predictors of virologic suppression and breakthrough in adolescents on HAART: Week 60 results from the PACTG 381 cohort. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.